Duloxetine-d₃ (hydrochloride)

Duloxetine-d₃ is intended for use as an internal standard for the quantification of duloxetine (Item No. 14317) by GC- or LC-MS. (S)-Duloxetine is a potent inhibitor of serotonin and norepinephrine reuptake (K_is = 4.6 and 15.6 nM, respectively, for rat synaptosomes).¹ It also inhibits dopamine reuptake (K_i = 369 nM). (S)-Duloxetine suppresses spontaneous firing activity in vivo in the dorsal raphe and locus coeruleus (ED₅₀s = 99 and 475 µg/kg, respectively).² It also decreases immobility time and increases latency to first immobility in the forced swim test in mice when administered at doses of 16 and 32 mg/kg.³ Formulations containing (S)-duloxetine have been used in the treatment of major depressive disorder, generalized anxiety disorder, chronic neuropathic and musculoskeletal pain, and fibromyalgia.

WARNING This product is not for human or veterinary use.

1. Wong, D.T., Bymaster, F.P., Mayle, D.A., et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8(1), 23-33 (1993).

2. Kasamo, K., Blier, P., and De Montigny, C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: In vitro and in vivo studies in the rat brain. J. Pharmacol. Exp. Ther. 277(1), 278-286 (1996).

3. Castagné, V., Porsolt, R.D., and Moser, P. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. Eur. J. Pharmacol. 616(1-3), 128-133 (2009).